Replimune Group Stock Forecast
NASDAQ: REPLHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
Market open · Delayed 15 min · as of Oct 8, 3:21 PM ET
REPL analyst consensus
Consensus (8 analysts)
buy
Avg. price target
$19.50+49.43%
- Strong buy 2
- Buy 5
- Hold 0
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 8 Wall Street analysts covering Replimune Group (2026-10-08), 7 rate the stock a buy or strong buy, 0 rate it a hold and 1 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $19.50, with a high estimate of $24.00 and a low estimate of $14.00. The average target implies upside of 49.4% from the current price of $13.05.
The spread between the highest and lowest targets is 71.4%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for REPL.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 2 | 25% |
| Buy | 5 | 63% |
| Hold | 0 | 0% |
| Sell | 1 | 13% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $14.00 | +7.28% |
| Average target | $19.50 | +49.43% |
| High target | $24.00 | +83.91% |